An interventional study of Transmagnetic Stimulation and Electroconvulsive Therapy in Treatment Resistant Depression (TRD), sponsored by Austin Messner. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Austin Messner · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.
Among the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 167th largest by enrollment of the 181 interventional ones that give a count, is one of 12 that started in 2025, is one of 72 with no phase, and was the 179th registered.
450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →43 of the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:
NeuroRx, Inc. · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 22–60
Motif Neurotech, Inc. · Sites in United States
Ages 22–85
BrainHealth Solutions, Inc. · Sites in United States
Ages 65+
Mclean Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
205 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 58 · Phase 3 23 · Phase 4 17
First in 2001; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1 is below the median of 58 across 373 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 38 across the 181 interventional studies, 66 across the 23 observational. Of the 120 that completed or were terminated, 70 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 205 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Austin Messner as lead sponsor.
Austin Messner has 1 study filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
20 of the studies in Depressive Disorder, Treatment-Resistant with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT04684706University of PennsylvaniaCompressed Intermittent Theta Burst Stimulation | 2026-11-30 |
| NCT06938841University of California, San DiegoMaintenance rTMS for Depression (Maitr-De) | 2026-11-30 |
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
| NCT07310381Stanford UniversityVagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement | 2026-12-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Electroconvulsive therapy (ECT) is one of the most efficacious treatments available for treatment-resistant depression (TRD). Although a maintenance ECT protocol exists, multiple barriers limit its use for long-term use. These barriers include procedure tolerability, cognitive side effects, financial burden, and unreliable social support to accompany patients for these treatments. On the other hand, a different modality of noninvasive neuromodulation called transcranial magnetic stimulation (TMS) can be performed in the outpatient setting and does not need anesthesia. The likelihood of cognitive adverse effects with TMS is much lower than with ECT. Our clinical question encompasses piloting a maintenance TMS regimen to maintain remission in treatment-resistant major depressive disorder.
This will be a patient-preference clinical trial, with patients offered the choice to initiate maintenance TMS versus maintenance ECT after their index ECT sessions for treatment-resistant depression. There will be no randomization or placebo involved in this study.
The clinical question encompasses piloting a maintenance TMS regimen to maintain remission in treatment-resistant major depressive disorder.
Patients who choose maintenance TMS will initiate maintenance TMS sessions on day one of the study and continue any currently prescribed pharmacotherapy. Participants will initiate TMS treatment within 1 week of last index ECT treatment. Participants will then follow a schedule of weekly for 4 sessions, every other week for 4 sessions, and monthly for 3 sessions for a total of 11 sessions in 6 months. Investigators will use the TMS paradigm called intermittent theta burst stimulation (iTBS), which was used in the SNT trial(Cole et al., 2022; Cole et al., 2020). At conclusion of the 6 month TMS portion of the study clinical judgement will be used to determine if the patient will return to maintenance ECT treatment. RBANS for assessment of cognition will be completed at the beginning, after 6 months, and at the conclusion of the study as well in both the standard of care and TMS portions of the study.
Those who choose maintenance ECT will transition to maintenance ECT treatments in the hospital as prescribed by their treating inpatient psychiatrists. On initial visit consent will be obtained and baseline cognitive and behavioral scales assessed as follows: Antidepressant treatment history form (ATHF), alcohol use disorder identification test (AUDIT-C), Hamilton Depression Rating Scale (HDRS), Clinical Global Impression (CGI), quick inventory of depressive symptomology (QIDS), Brief Psychiatric Rating Scale (BPRS), Drug Abuse Screening Test (DAST-10), Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS), standardized assessment of personality abbreviated scale (SAPAS). Patients will then be asked to return at 6 month and 12 month intervals to repeat HDRS, QIDS, RBANS, and CGI scales.
Research data will be collected primarily through self assessment scales including Antidepressant treatment history form (ATHF), alcohol use disorder identification test (AUDIT-C), Hamilton Depression Rating Scale (HDRS), Clinical Global Impression (CGI), quick inventory of depressive symptomology (QIDS), Brief Psychiatric Rating Scale (BPRS), Drug Abuse Screening Test (DAST-10), Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS), standardized assessment of personality abbreviated scale (SAPAS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who have achieved remission of treatment resistant depression through an initial course of ECT (8 to 12 sessions) at the University of Kentucky will be identified by the ECT attending physician as a candidate for this study. They will receive TMS in this arm of study for maintenance treatment of their depression and monitored with depressive scales.
Device: Transmagnetic Stimulation
Patients who have achieved remission of treatment resistant depression through an initial course of ECT (8 to 12 sessions) at the University of Kentucky will be identified by the ECT attending physician as a candidate for this study. If they elect to continue with maintenance ECT treatments which is the current standard of care, their depressive symptoms and cognitive functioning will be monitored accordingly.
Device: Electroconvulsive Therapy
TMS will be given for the maintenance treatment of treatment resistant depression following successful course of ECT (8-12 treatments).
Also known as: TMS
Patients will remain in standard of care treatment and receive maintenance ECT treatments for treatment resistant depression
Also known as: ECT
Change in Hamilton Depression Rating Scale (HDRS)
One of the most widely used clinician administered depression scales containing 17 items. Scores range from 0 to 54 with 0-7 being normal, 8-16 being mild depression, 17-23 moderate depression and 24 or greater being severe depression. Higher scores equate to more severe depressive symptoms.
Time frame: Baseline and prior to each procedure for duration of study, up to six months
Change in Quick Inventory of Depressive Symptomatology (QIDS)
A widely used self-report scale of depression with similar validity to the HDRS that consists of 16 scale items. Scores range from 0 to 27 with 0-5 indicating no depression, 6-10 mild depression, 11-15 moderate depression, 16-20 severe, and 21 or higher very severe. Higher scores equate to more severe depressive symptoms.
Time frame: Baseline and prior to each procedure for duration of study, up to six months
Change in Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS)
Cognitive screening tool that is individually administered battery to measure cognitive decline or improvement. Scores range from 40 to 160. 69 and below is extremely low, 70-79 borderline, 80-89 low average, 90-109 average, 110-119 high average, 12-129 superior, and 130+ very superior. Higher scores equate to better cognitive functioning.
Time frame: Baseline on initial presentation, at 6 months, and at 12 months
| Milestone | Transcranial Magnetic Stimulation (TMS) | Electroconvulsive Therapy (ECT) |
|---|---|---|
| Started | 1 | 0 |
| Completed | 0 | 0 |
| Not completed | 1 | 0 |
One of the most widely used clinician administered depression scales containing 17 items. Scores range from 0 to 54 with 0-7 being normal, 8-16 being mild depression, 17-23 moderate depression and 24 or greater being severe depression. Higher scores equate to more severe depressive symptoms.
No measurements were reported for this outcome.
A widely used self-report scale of depression with similar validity to the HDRS that consists of 16 scale items. Scores range from 0 to 27 with 0-5 indicating no depression, 6-10 mild depression, 11-15 moderate depression, 16-20 severe, and 21 or higher very severe. Higher scores equate to more severe depressive symptoms.
No measurements were reported for this outcome.
Cognitive screening tool that is individually administered battery to measure cognitive decline or improvement. Scores range from 40 to 160. 69 and below is extremely low, 70-79 borderline, 80-89 low average, 90-109 average, 110-119 high average, 12-129 superior, and 130+ very superior. Higher scores equate to better cognitive functioning.
No measurements were reported for this outcome.
Collected over Only 1 participant was enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Transcranial Magnetic Stimulation (TMS) | — | — | — |
| Electroconvulsive Therapy (ECT) | — | — | — |
0 participants enrolled in the ECT arm
| Age, Categorical(Participants) | Transcranial Magnetic Stimulation (TMS) | Electroconvulsive Therapy (ECT) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Transcranial Magnetic Stimulation (TMS) | Electroconvulsive Therapy (ECT) | Total |
|---|---|---|---|
| Female | 1 | 0 | 1 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Transcranial Magnetic Stimulation (TMS) | Electroconvulsive Therapy (ECT) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Transcranial Magnetic Stimulation (TMS) | Electroconvulsive Therapy (ECT) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 1 | 0 | 1 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Transcranial Magnetic Stimulation (TMS) | Electroconvulsive Therapy (ECT) | Total |
|---|---|---|---|
| United States | 1 | — | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Apr 2025 to primary completion in Jun 2025, 2 months.
Results were first posted in May 2026, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Depressive Disorder, Treatment-Resistant →